Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00526084|
Recruitment Status : Unknown
Verified December 2005 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : September 6, 2007
Last Update Posted : September 6, 2007
Emerging results suggest that a cure rate of nearly 90 percent will be attained in the near future. The advance was attributed to stringent application of prognostic factors for risk factor-directed therapy. Early response to treatment has greater prognostic strength than does any other biologic or clinical feature tested to dates. The measurement of minimal residual disease(MRD) affords a level of sensitivity and specificity that cannot be attained through traditional microscopic morphologic assessments. In Taiwan, detection for the most recurrent fusion genes and the MRD were not commonly available, the TPOG(Taiwan Pediatric Oncology Group) used clinical features, immunophenotypes, and cytogenetics to do risk group classifications and protocol assignment. A successful rate of 60-70% has been reached. In order to improve the cure rate of ALL in Taiwan, this project aims at establishing the methods for better risk classifications and establishing MRD detection for risk-directed therapy for childhood ALL in Taiwan.Intrinsic and acquired resistances to multiple anticancer agents represent major obstacles and accounts for 10-20% of treatment failure in the developed countries nowadays. Recent progress using DNA microarray identified differential expression level of the genes known to implicate in cell cycle control, DNA repair and apoptosis in different subsets of ALL patients, which were found to be related to drug response. Genetic polymorphisms in the genes of drug-metabolizing enzymes, drug transporters or drug targets, can influence the efficacy or toxicity of antileukemic agents. Specific genotype might be important in determining the pharmacokinetic effects of one population or disease subtype from that in others. Recently, the expression profiles of relatively few microRNAs (miRNAs) (~200 genes), was noted to accurately classify human cancers. These informations hinted that expression of the genes in the leukemic cells might serve as additional risk factors for treatment stratification.
Specific aims and goals:
- to establish better risk factors classification and use MRD to monitor early response to treatment.
- to establish the expression profiles of 12 genes associated with drug resistance
- to unravel the pharmacogenetic background of pediatric ALL in Taiwan, so that will help refine the therapy dose, achieve a better drug effect and avoid acute or chronic toxicity.
- microRNA expression profiles in childhood ALL in Taiwan
|Condition or disease|
|Leukemia, Lymphocytic, Acute|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Observational Model:||Defined Population|
|Official Title:||Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan|
|Study Start Date :||March 2007|
|Estimated Study Completion Date :||December 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00526084
|Contact: Yung-Li Yang, MD||886-968663341 ext email@example.com|
|Contact: Dong-Tsamn Lin, MD||886-2-23123456 ext firstname.lastname@example.org|
|Taipei, Taiwan, 100|
|Contact: Chung-Yi Hu, PhD 886-2-23123456 ext 6914 email@example.com|
|Contact: Dong-Tsam Lin, MD 886-2-23123456 ext 5399 firstname.lastname@example.org|
|Principal Investigator: Chung-Yi Hu, PhD|
|Principal Investigator:||Chung-Yi Hu, PhD||Department of Clinical Laboratory Sciences and Medical Biotechonology|
|Principal Investigator:||Shu-Wha Lin, PhD||Department of Clinical Laboratory Sciences and Medical Biotechonology|
|Principal Investigator:||Lan-Yang Chang, PhD||Department of Clinical Laboratory Sciences and Medical Biotechonology|